US-based genome engineering platform developer Synthego received $100m in series D financing on Wednesday from investors including semiconductor and data technology producer Intel’s corporate venturing unit, Intel Capital.
Venture capital firm 8VC and investment managers Wellington Management and RA Capital Management co-led the round, which also featured Founders Fund and Menlo Ventures.
Synthego has developed technology platforms equipped with machine learning, automation and gene editing technology that produce engineered cells and standardised reagents for Crispr gene editing. The series D funds will go to adding more capabilities to its products.
The round boosted the company’s overall funding to $260m and came in the wake of a $110m series C in late 2018 that was led by Founders Fund and backed by 8VC and Menlo Ventures.
8VC led Synthego’s $41m series B round in 2017, which was also backed by real estate investment trust Alexandria Real Estate Equities, AME Cloud Ventures, Elements Capital, OS Fund, ZhenFund and existing investors Founders Fund, Menlo Ventures, WI Harper Group and SciFi VC.
Paul Dabrowski, Synthego’s co-founder and CEO, said: “Working with dozens of world-class academic institutions and top Fortune 500 biopharmaceutical companies that have contributed to our progress in transforming the life sciences, we are pleased to have such strong investor support as we continue to execute on our vision and platform technologies, which enable scientists to rapidly discover and develop new therapies for serious diseases.”
